Procept BioRobotics specializes in advanced medical technologies, particularly focusing on Aquablation therapy, which is a robotic-assisted treatment for benign prostatic hyperplasia (BPH). The Aquablation therapy utilizes a unique ultrasound-guided, waterjet approach that allows for precise tissue resection while preserving critical anatomical structures. This technology is designed to provide significant and lasting symptom relief for patients, regardless of prostate size or shape, while minimizing the risk of irreversible complications such as erectile dysfunction and incontinence. The HYDROS Robotic System, integral to this therapy, enhances the predictability and personalization of treatment, empowering surgeons to optimize patient outcomes.

The efficacy and safety of Aquablation therapy are supported by a robust body of clinical data from multiple studies, including the WATER, WATER II, OPEN WATER, and JAPAN PMS trials. These studies demonstrate that Aquablation therapy not only matches but, in some cases, surpasses traditional treatments like TURP in terms of symptom reduction and quality of life improvements. The results indicate a low rate of complications and high durability of outcomes, reinforcing the therapy's effectiveness across a diverse range of prostate sizes and shapes. Procept BioRobotics is committed to advancing men's health through innovative technologies that prioritize patient safety and treatment efficacy.

United States

PROCEPT BioRobotics is a medical robotics company that specializes in minimally invasive robotic surgery technology.

Procept BioRobotics

Company Details